Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy - PubMed
5 hours ago
- #antithrombotic strategy
- #platelet aggregation
- #integrin β3
- Current antiplatelet drugs inhibit platelet aggregation but increase bleeding risk because they block integrin αIIbβ3 activation needed for hemostasis.
- Researchers developed an antibody targeting the β-tail domain of integrin β3 to selectively inhibit force-induced activation, which is key in pathological thrombosis.
- The antibody specifically blocks force-dependent αIIbβ3 activation, suppressing platelet aggregation in ex vivo and in vivo models without causing bleeding.